Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience

S. Chiara, S. Mammoliti, C. Oliva, L. Merlini, M. Bruzzone, M. R. Sertoli, G. C. Parodi, N. Ragni, G. Foglia, F. Odicino, G. Parodi, L. Iskra, F. Carnino, E. Guercio, P. F. Conte, R. Rosso

Research output: Contribution to journalArticlepeer-review


87 patients with high risk of recurrence FIGO stage I and II ovarian carcinoma were treated with adjuvant chemotherapy consisting of cisplatin 50 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 every 28 days for 6 courses. Toxicity and efficacy of the regimen was evaluated after a median follow-up of 45 months. Treatment-related toxicity was mild and reversible, consisting chiefly of acute WHO grade 2 myelosuppression (10% of patients) and controllable grade 3 emesis (55%). No late toxicity was observed. Actuarial 7-year survival and relapse-free survival (RFS) were 76% and 61%, respectively; a statistically significant difference in outcome was observed for undifferentiated grade tumour (G1 vs G2 vs. G3: P <0.01) but not for FIGO stage disease (stage I vs. stage II). In our opinion, short-term chemotherapy including the most active single agent, i.e. cisplatin, appears a tolerable and effective treatment which deserves further evaluation in large randomised trials.

Original languageEnglish
Pages (from-to)1211-1215
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number10
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience'. Together they form a unique fingerprint.

Cite this